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Introduction 
We live in an era of specialization. Yet biotechnology, used 
here in the restricted sense of recombinant DNA technology, 
is presenting society with profound issues that will require 
diverse interdisciplinary talent and thinking for solution. In 
order to understand the implications of the use of a geneti-
cally engineered organism ( GEO) in an agricultural or envir-
onmental application, for example, it may be necessary to 
understand subtle implications of 1) its molecular biology, 2) 
its organismal and population biology, 3) its potential for 
microevolutionary adaptive change, 4) the local ecology, 5) 
the local socioeconomics, and 6) the national and interna-
tional context of economics and technological development. 
Someone who is trained to make genetic alterations to 
produce one desired goal; e.g. , a bacteria that produces a new 
useful chemical, is not necessarily educated to anticipate, to 
recognize, or to study the complex implications of such 
genetic changes for the complete habits of the living orga-
nism. Moreover, as in medicine, much art and hands-on expe-
rience goes into even an imperfect understanding of how a 
change in one part of a living organism may alter its functions 
and habits. Good theories do not yet exist to explain just how 
changing a few genes may change the complete adult orga-
nism. Science is several Nobel Prizes away from that. 
It is molecular biologists and genetic engineers who hold 
the powerful tools for creating new forms of life. Theirs are 
fast-moving, competitive, and demanding fields. They do not 
usually have the time, incentive, or institutional support to 
equip themselves to deal more than superficially with the 
complex biological, economic, institutional, and ethical 
issues that their technology generates. They are typically bio-
chemists or laboratory microbiologists who are learning to 
extend their techniques to the manipulation of new tissues 
such as those of plants, animals, and "wild-type," nonlabora-
tory, microorganisms. Where shall society get the counsel that 
it deserves? It is widely believed that biotechnology will 
impact upon human affairs as profoundly as the Industrial 
Revolution. Yet, scientists of various types are being thrust into 
positions of responsibility and power for which their back-
grounds do not prepare them. 
The development of biotechnology is most likely to be 
effective, efficient, and fair if society develops a competent 
infrastructure to deal with it. This would include a diverse 
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body of appropriately educated scientists, scholars, policy-
makers, and ordinary citizens who can make good judgments 
about what are, in many cases, unprecedented issues. It would 
also include networking modes both outside and within 
government and industry for information and talent exchange, 
and for participation in decisionmaking. 
Societies have a way of muddling along and many people 
expect and aspire to no more. They need read no further. This 
communication is not for them. It may not be the end of the 
world if biotechnology is not wisely handled. But I write with 
the basic presumption that the reader is interested in explor-
ing some alternatives to leaving this issue to the generosity of 
fate , and to the skills of poorly prepared professionals. I 
elaborate now on the issue of need. Some more specific 
suggestions for the types of talents needed, especially in biol-
ogy, are discussed in Regal (1) . 
Historical Difficulties for Public Discussion 
There is much uncertainty and little consensus about the 
seriousness of any one of the following issues. The state of 
uncertainty has led to a statistical spread of opinion on each 
issue-some people are surely underconcerned while others 
are overconcerned As is usual in human affairs, the extreme 
positions often react strongly and with outrage to each other's 
excesses and are also the most visible in public debate. The 
middle gets neglected or is misrepresented, and the standards 
for public discussion remain low. This polarization can dis-
courage conscientious and thoughtful citizens from participa-
tion in matters that will affect them and their children. 
It cannot be emphasized too strongly that the polarization 
today in large part is a legacy from "the great debate" of the 
1970s, which centered on the possibility of a laboratory acci -
dent that might produce an "Andromeda Strain" (2, 3, 4). 
Analysis and experience have shown that the emotional con-
cerns were highly excessive. I.aboratory strains are unlikely to 
survive and spread in nature. Any new pathogens can be 
handled relatively safely with established methods. 
New questions have been raised, though, concerning orga-
nisms that are engineered to be competitive in nature. It is 
diffiCult, for example, to predict the effects of the introduction 
into nature of vigorous bacterial "goats" or weedy plants 
engineered to "eat up," or metabolize, a range of chemicals 
including environmental pollutants. Even costly misjudg-
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ments here would probably not have the dramatic severity of 
an "Andromeda Strain" (5, 6, 7). Yet some influential scientists 
greatly fear that the exploration of relatively modest environ-
mental or health concerns will reopen the lid ofPandora's box 
to the reputed crazy, hysterical fears of"killer tomatoes," and 
the "corn that invaded the Bronx." 
Some in biotechnology see any efforts to put scientific, 
social, institutional, or economic concerns into perspective 
merely as irresponsible lid-raising. They live in dread of 
renewed "public hysteria." They would seem to have a point 
since subtle thought is not commonly encountered. Yet, the 
American public has, in fact, been generously supportive of 
biotechnology, despite "the great debate" and it does not 
seem realistic to sweep legitimate public concerns under the 
rug putatively to save the industry. 
Indeed, the public has come very much to want genetic 
engineering. When local governments and the courts have 
delayed projects, and Congress has shown concern, it has 
often been because of suspicions raised by industrial secrecy 
and by the impressions of insufficient discussion among 
experts of potential consequences. Concern exists that the 
American institutions of due process, thorough discussion, 
and of checks and balances may be circumvented. Actually, 
one hears almost no serious concern for "sludge monsters" 
anymore. Without understanding their history, it would be 
hard to understand why genetic engineers often equate all 
public concerns with ignorance and hysteria. 
The situation that has resulted is most unfortunate, but its 
very irrationality and superficiality underscores the profound 
extent of the unknowns and the critical need for public vehi-
cles to promote responsible discussion of such issues. In this 
sense, and with this warning, it is useful to list issues of 
potential concern. This list should in no way be taken to slight 
the immense potential benefits ofbiotechnology, which have 
been widely discussed. On the contrary, the aim is to devise 
ways to realize the benefits of the new technology. 
Pragmatic Concerns 
In a pluralistic society, policy debate is more likely to focus 
on pragmatic concerns of national security, the economy, 
health, the environment, justice, and institutional vitality than 
of issues with a distinct sectarian basis. The following prag-
matic concerns have been raised in a number of books and 
articles by knowledgable people. 
Security 
Biological warfare arms-race seems to have been renewed 
with the Soviet Union. The potential dangers are disputed 
by the experts (8)." 
Terrorism. Cheap and psychologically powerful threats 
could become available, some experts warn. 
Economic 
Loss in the United States' competitive position if any obsta-
cles to development are created. This is a major belief in 
industry and Washington. 
Misdirection of public funds to support private interests 
against public interests. (For example, increased milk pro-
duction might help some scientists and dairy people to 
profit, but hurt the industry and the taxpayers who subsid-
ize surpluses; may hurt the national and international 
economies.) 
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Health 
Misdesign leading to diseases or to harmful side effects. 
(For example, it is not widely appreciated that some vec-
tors could theoretically have carcinogenic effects. There 
may be sufficient safeguards in the system already to 
explore such issues in timely fashion.) 
Neglect of nonprofitable illnesses. (e.g., in the early 1980s a 
leading company would not develop an antimalarial vac-
cine for the World Health Organization unless assured a 
monopoly on the profits (9), despite public funding of 
research.) 
Environmental 
Mismanagement of nature with powerful new technology. 
Ability to alter nature expected to advance faster than ability 
to understand the implications of this. 
Misdesign leading to rogue species. Genetic engineering is 
not true engineering where the properties of materials and 
designs are well understood and results are highly predict-
able. Airplanes and bridges are not subject to pleiotropic 
effects, genetic rearrangements, adaptive plasticity. 
justice 
Commercial takeover of publicly developed technology. 
Federal, state, and foundation funds have developed bio-
technology. Is it fair for private companies to "run off' with 
all the profits? If not, who should get what? Universities are 
trying to obtain profits, but currently they are spending 
more than many believe they can expect to gain. How 
much do they deserve? 
Should a particular researcher's or company's project be 
delayed because of concerns over broader social or eco-
nomic issues, or because of hypothetical concerns over 
health or safety? 
Private, corporate experimentation with the environment, 
with "the commons." Who should be allowed to experi-
ment with nature in ways that may not be able to be 
undone? How freely? Who does nature belong to? 
Passing any mistakes on to other countries, future 
generations. 
Should the public pay the costs of any health, environmen-
tal mistakes, or of any institutional dislocations by industry? 
Who will make important decisions with possibly pro-
found economic, social, moral, and environmental conse-
quences? Who will assume these powers? The market-
place? Bureaucracy? Politicians? Courts? Other? 
Institutional 
Does ease of entrepreneurial activity create new qualitative 
or quantitative dimensions of conflict of interest for aca-
demic scientists? Concentration of political control in 
' biology? 
Loss of the university, National Academy, etc., as societal 
resources for objective analysis and forums for scholarly 
debate. Panem (10) and Murray (9) discuss additional 
aspects of this complex general issue. 
Development of a "University-Industrial-Federal Com-
plex." 
Concentration of power over agricultural/rural America 
(and internationally) in the hands of an agribusiness-
university-USDA complex. 
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Industry may need so much political and economic sup-
port that the fundamental relationships of government to 
industry may transform radically. (For example, govern-
ment subsidy of industry through technology development 
and economic leverage on universities, or patenting of life, 
which has long been regarded as property of "the com-
mons," or relaxed regulations.) 
Theological/Phllosophical Concerns 
Most religions and philosophies do not seem to have iden-
tified concerns about the creation of new life forms. However, 
some in the Greco-Christian tradition strongly question violat-
ing the natural order of things. The natural order is seen as 
reflecting the intentions of God, or the will of God. Changing 
that, particularly for selfish reasons, or with overt or covert 
motives of self-love, or pride, is seen as defiance of the will of 
God. 
Genetic manipulation of the unborn, of germ lines, is 
widely agreed to be morally unacceptable. This is not a sectar-
ian issue in the United States. It seems quite unlikely that 
Western Society will be creating reproducing lines of geneti-
cally engineered super-soldiers, airline pilots, or basketball 
players. 
Socioeconomic Obstacles to the Development of 
an Infrastructure · 
Industry 
The biotechnology industry has raised an enormous amount 
of venture capital. It is based on enormous public investments 
in basic research, but it has not yet produced significant 
income for this $15 to 20 billion investment. Individuals are 
pr~oc~upied with presenting a positive, fresh, exciting image 
of mdividual, corporate, and industry progress and with sus-
taining the interest of investors. They are busy trying to 
develop products. These are matters of survival. 
The industry has had its own problems. It has been com-
mon to find scientists who know little about business and 
businesspeople who know little about science trying to com-
pete in complex ventures. Organisms have proved to be more 
difficult to work with than the molecular biologists antici-
pated (recall the unearned Nobel Prizes mentioned above) 
and progress has been slower than projected on many projects 
(11). 
There is hardly time to think about a broad societal infra-
structure. There are no obvious personal incentives for this. 
Indeed, industry may see talk of a need for an infrastructure as 
raising concerns to venture capitalists that could threaten a 
company's image and survival. They may tend to label such 
talk as "negativism" or "doom and gloom." It is in the eco-
nomic interests of the industry as a whole to minimize poten-
tial risks and problems. But, it may be difficult for individuals 
to advance up career ladders, and be seen as "team players," 
unless they voice personal concerns discreetly and balance 
broad concerns with optimistic enthusiasm for industry pros-
pects. That would not be the easiest path to follow for many 
ambitious people. The issue is made particularly difficult 
since the public concerns are often of a broad and general 
nature, and the seriousness of their impact is necessarily 
uncertain in these early days. 
In the most cynical scenario, the dynamics of self-interest 
would threaten to lead toward a group psychology of stone-
walling, or even denial, in the biotechnology industry that 
could be parallel to that in, for example, the tobacco industry. 
Here, the industry adopted a self-serving group perception 
based on the early questionable nature of the arguments 
linking smoking and cancer. By the time the data had 
improved, the industry had become "philosophical" and 
closed-minded. Even faced with damning statistical data, one 
could always argue, for example, that the sale of a single 
package of cigarettes carries a vanishingly small probability of 
risk. So if any issue exists, it can only be in abuse of the 
product. 
Scientists in the biotechnology industry have assured me 
that widespread concern exists within the industry itself for 
the issues raised here and that biotechnology is still far from 
being absorbed in a dialogue of denial. Yet even these con-
cerned scientists generally agree that some socioeconomic 
factors in industry work against the development of an infra-
structure to deal with concerns. 
Appealing to the long-term interests of the industry is more 
likely to be effective with large companies that take long-
range corporate outlooks. But even here uneasiness exists 
since there is uncertainty about prospects for profit, and since 
biotechnology programs must justify themselves in the short-
run to major shareholders against other company options. 
Smaller companies are generally less able to give attention 
to societal issues since survival is more nearly a daily concern. 
Many small companies foresee eventually selling out to larger 
companies and may not take a long-range outlook in any 
event. 
The University 
Academic molecular biologists and genetic engineers are 
not necessarily free of socioeconomic influences. It can be 
relatively inexpensive to apply for a patent and form a small 
biotechnology company. Many have done this, even running 
companies on university property. The line between federally 
funded, "open" research and business activities often cannot 
be drawn. It may not be clear which hat the scientist and his 
students and technicians are wearing at any given moment. 
This has already led to divisive problems at universities every-
where. The extent and nature of business-related activity on 
campus may not even be discernable, given the nature of the 
work and funding. 
Moreover, extensive networking exists that makes it diffi-
cult to obtain disinterested counsel from scientists. A profes-
sor may not have his own company, but perhaps his collabora-
tors or his own graduate advisor holds stock and sits on the 
board of some companies. His graduate students may have 
taken positions at other universities and formed their own 
companies there. 
The issue of"power" is never far off. Within science and the 
academy, who should have the power to say how genetic 
engineering should be developed? Who should control the 
dialogue and the agenda of discussion? It becomes harder for 
genetic engineers to admit others into the discussion when it 
seems that the discussion on campus could affect business 
prospects and may not remain purely "academic." 
Every book that I have seen in this area warns that biotech-
nology will present unusually severe challenges for universi -
ties. Yet, for whatever reasons, university policies are usually 
to proceed full steam ahead with development programs and 
to ignore opportunities to explore the broader implications of 
biotechnology. Perhaps it generally is as one dean told me 
plainly when I raised this issue a few years ago, "Don't assume 
that there is any group of wise men that sits around to decide 
what is right and how to do it. This is a very political place. 
Money talks, and political clout." 
Many university administrators encourage campus involve-
ment with business. In part, this is because career ladders can 
be influenced by the size of the budget an administrator 
controls or has jurisdiction over. In part, this is also because 
business and government ties are often important in campus 
politics. There is also clearly some truth to the argument for 
public consumption that more money means larger programs 
and more activity. The implication that this necessarily means 
higher quality scholarship or more "important" scholarship is 
notoriously open to dispute. 
Ecologists, too, as other scientists and scholars, are con-
fined by their own training, disciplinary boundaries, and 
grant-renewal agendas. They are focused on their own career 
ladders and have their own interests. 
Biotechnology raises exciting intellectual issues for scho-
lars not only in biology but also in economics, sociology, 
agriculture, philosophy of science, political science, interna-
tional relations, and the humanities. But disciplinary isolation 
and campus politics create inertia against taking up such 
issues in more than a sporadic way. New external funding 
could counter such inertia. Departments and administrators 
are unlikely to give priority to hiring new faculty, giving merit 
raises, space, time, etc., unless external funding seems secure. 
There is presently no rush to fund studies and education in 
these areas. 
The National Academy of Sciences has often been criticized 
for not being able, as a body, to maintain a sufficiently disin-
terested stance on public issues because many of its members 
in physics, chemistry, engineering, and now molecular biol-
ogy have ties to business and the military. For whatever rea-
sons, it has largely pushed for rapid development and has not 
volunteered an agenda for meeting the public concerns men-
tioned here. 
Government 
The priority in government is to develop biotechnology as 
rapidly as possible. In part, this is because the economy has 
been bad for some years and it is hoped that biotechnology 
can offer some relief to local and national problems. Politi-
cians see the overriding concern of voters to be economic 
recovery. Other public concerns seem "philosophical" or 
"idealistic" in this light. 
Health and environmental concerns are seen as having 
enough political currency to merit attention at some level. 
Around these issues a small infrastructure has developed of 
informed scientists on congressional staffs, and in agencies 
such as the National Science Foundation, and especially the 
Environmental Protection Agency (EPA). The EPA began its 
preparations relatively early, in anticipation of the need to 
evaluate proposals for introductions of GEOs into ,the 
environment. 
There is even a small amount of funding available for 
individual, particular research grants that may be helpful here. 
So far these funds have come from other programs and have 
been criticized for this reason. There has not been funding for 
scholars to study and consider broad issues, or for a broad 
interdisciplinary education effort. Nor have funds been 
appropriate to the scale of the issue. 
A Catch-22 is part of the problem. Some congressional 
leaders are urging the development of vehicles to meet 
broader concerns. But they are wisely reluctant to appropriate 
funds until they are certain that the money can be well used 
and will not simply be absorbed by ever-present opportunists 
for traditional uses under new labels. Scientists and scholars, 
though, are reluctant to invest the time and effort to educate 
themselves deeply on these complex issues unless they can 
foresee secure funding. 
The intellectual and political support of industry has been 
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sought in developing a national agenda. But as mentioned, 
the priority of industry is to develop rapidly and it has been 
reluctant to agree that the study of broader social concerns is 
its problem. 
A second sort of infrastructure is developing around issues 
related to agriculture and biotechnology. This too is modest in 
size. 
The few qualified people on the Washington scene work 
long and hard and much of their energy is absorbed by topical 
issues such as regulation. They seem to change agencies often 
and this also absorbs much energy. Some leave government 
payrolls to become lobbyists and consultants. It is not clear 
how much time, energy, and freedom they have to contribute 
to the elucidation and solutions of the concerns collected 
above. In any event, biotechnology is here to stay and the 
range and complexity of the present and potential issues 
dwarf the available talent. 
Recently, I have seen the emergence of some informed 
people in state agencies, primarily in connection with regula-
tory issues. It is not clear if this is the start of a trend or in what 
direction such a trend might lead. 
Conclusions 
Ideally, scientists, scholars, and qualified citizens would be 
financially and politically free to interact and to study and 
prepare to offer wise counsel on the interesting and profound 
challenges that our new technological future is presenting to 
society. They could contribute greatly to the development of a 
sound policy and to the development of necessary institu-
tional changes. They could help educate a generation to meet 
the mushrooming challenges of the future. The system is not, 
though, set up by itself to encourage and support such free 
inquiry. Free inquiry is discouraged by 
1) a polarized and emotional controversy with a confused 
history and hardened perceptions on the part of some; 
2) intrinsically complex interdisciplinary issues; 
3) the disciplinary politics and financial incentive structures 
of academics; 
4) the direct financial interests of many scientists and of the 
public organizations in which they have power; 
5) the fear of raising issues that may slow development. 
So where shall society get its wise counsel?Will it do to have 
the individual thinker here and there who writes an occa-
sional book, or who does his or her job well? The lesson of 
history is that such individual efforts will merely spotlight the 
folly that tends to unfold when serious issues are ignored on 
an institutional level. We will need new and focused political 
and economic support for programs to educate people who 
can grasp the details of these issues, research them, work out 
sound policies, and answer specific questions at an appro-
priate level of detail and understanding. 
References 
1. Regal, P.]. 1987. Safe and effective biotechnology: mobil-
izing scientific expertise. (In press) In: John Fowles III 
(ed.) Application of Biotechnology: Enviromental and 
Policy Issues. AAAS Symposium. Boulder, Colorado: West-
view Press. 
2. Jackson, D.A., and Stitch, S.P. (eds.) 1979. The Recombi-
nant DNA Debate. Englewood Cliffs, New Jersey: Prentice-
Hall. 
3. Krimsky, S. 1982. Genetic Alchemy: The Social History of 
the Recombinant DNA Controversy. Cambridge, Massa-
chusetts: MIT Press. 
31 
4. Watson,J.D. , and Tooze,J. 1981. The DNA Story: A Docu-
mentary Story of Gene Cloning. San Francisco: W.H. 
Freeman and Company. 
5. Regal, P J. 1985. The ecology of evolution: implications of 
the individualistic paradigm. In : H. Halvorson, D. Pramer, 
M. Rogul (eds.), Engineered Organisms in the Environ-
ment, pp. 11-19. Washington, D.C.: American Society for 
Microbiology. 
6. Regal, P.]. 1986. Models of genetically engineered orga-
nisms and their ecological impact. In: H. Mooney and]. 
Drake (eds.) , Ecology of Biological Invasions of North 
America and Hawaii, pp. 111-129. NewYork: Springer-
Verlag. 
7. Regal, PJ. , 1986. Natural history in the era of genetic 
engineering. Imprint3(4): 1-3, 8. QFB Museum, Univer-
sity of Minnesota) 
8. Wright, S., 1987. New designs for biological weapons. 
Bull of the At. Sci. 43(1) : 43-46. 
9. Murray, T J. 1985. Ethical issues in genetic engineering. 
Social Res. 52: 471-489. 
10. Panem, S. 1984. The Interferon Crusade. Washington, 
D.C.: The Brookings Institution. 
11. Yanchinski , S. 1987. Boom and bust in the bio business. 
New Scientist, jan. 22, 1987. 
General References 
1. jonas, H. 1985. Ethics and biogenetic art. Social Res. 52 : 
491-504. 
2. Kenney, M. 1986. Biotechnology: The University-Industrial 
Complex. New Haven, Connecticut: Yale University Press. 
3. Novick, R. , 1987. Bullish on DNA. (Review of Biotechnol-
ogy: The University-Industrial Complex by M. Kenney) 
New York Times Book Review. Feb. 15, 1987. 
4. Price, DJ. de Solla. 1986 ( 1963). Little Science, Big Science 
and Beyond. New York: Columbia University Press. 
5. Regal , PJ. 1985. Review of The Gene Business: Who 
Should Control Biotechnology?, by E. Yoxen. Bioscience 35 
(9): 596-8. 
6. Regal, PJ. 1985. Review of Recombinant DNA Research 
find the Human Prospect by E.D. Hanson (ed.) Bio-
science 35 (9): 596-8. 
7. Yoxen, E. 1983. The Gene Business: Who Should Control 
Biotechnology? New York: Harper & Row. 
A Broad Perspective on Biotechnology 
and Environmental Regulation 
GLENN L. RADDE 
Glenn L. Radde is a Senior State Planner in the Office of Planning at the Department of Natural Resources. 
I think that it is of the utmost importance to keep the 
political and scientific sides of biotechnology well balanced 
within the realm of public policy. There are at least two 
discernible groupings of people regarding biotechnology. 
There are those who sing its praises and those who ponder 
how little we really know of basic life processes. 
In the public policy arena, government is often caught in a 
netherworld between promises and realities-where it is 
often difficult to find truly honest, impartial advisors. While 
the public expects the government to act on everyone's 
behalf, interest groups representing the "public" get espe-
cially upset when they are slighted. For example, it is hard for 
anyone to deny a company help that is willing to invest large 
amounts of money in economically depressed areas. It is 
equally hard for an elected official to ignore companies who 
create more jobs than the typical margin of victory in local 
elections. 
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Very briefly, environmental regulation in the biotechnology 
area stems from the efforts in the 1970s of various federal 
agencies (e.g., National Institutes of Health (NIH), National 
Science Foundation (NSF), Environmental Protection Agency 
( EPA). In December, 1984, the White House Office of Science 
and Technology published in the Federal Register a "Proposal 
for a Coordinated Framework for Regulation of Biotechnol-
ogy" to standardize and harmonize the federal agencies' regu-
latory posture (1 ) . 
Within this document, the EPA, Food and Drug Administra-
tion (FDA), and U.S. Department of Agriculture (USDA) pub-
lished statements of policy defining the areas of biotechnol-
ogywith which they would be most concerned. FDA was to be 
concerned only if undesirable foreign materials are intro-
duced into pharmaceutical or food preparations. USDA saw no 
difference between recombinant DNA-derived plants and tra-
ditional crossbred variants. Finally, EPA considered its role to 
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